Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies
Cancers · 08.12.2023 · 15 (24) · 5765
DOI: 10.3390/cancers15245765 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.12.2023. Verfasst von Wioletta Olejarz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CAR-T cell therapy has revolutionized the treatment of hematological malignancies with high remission rates in the case of ALL and NHL. This therapy has some limitations such as long manufacturing periods, persistent restricted cell sources and high costs. Moreover, combination regimens increase the risk of immune-related adverse events, so the identification new therapeutic targets is important to minimize the risk of toxicities and to guide more effective approaches. Cancer cells employ several mechanisms to evade immunosurveillance, which causes resistance to immunotherapy; therefore, a very important therapeutic approach is to focus on the development of rational combinations of targeted therapies with non-overlapping toxicities. Recent progress in the development of new inhibitory clusters of differentiation (CDs), signaling pathway molecules, checkpoint inhibitors, and immunosuppressive cell subsets and factors in the tumor microenvironment (TME) has significantly improved anticancer responses. Novel strategies regarding combination immunotherapies with CAR-T cells are the most promising approach to cure cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Centre for Preclinical Research, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
ORCID-Profile: Wioletta Olejarz, Grzegorz Basak
Zitieren
APA
Olejarz, W., & Basak, G. (2023). Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. Cancers, 15(24), 5765. https://doi.org/10.3390/cancers15245765
Vancouver
Olejarz W, Basak G. Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. Cancers. 2023;15(24):5765. doi:10.3390/cancers15245765
BibTeX
@article{Olejarz2023,
author = {Olejarz, Wioletta and Basak, Grzegorz},
title = {Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies},
journal = {Cancers},
year = {2023},
volume = {15},
number = {24},
pages = {5765},
doi = {10.3390/cancers15245765}
}
EUVIMED